Press Release: Serametrix : ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

SAN JOSE, Calif., March, 27, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated...